Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine.
We report 5 cases of acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Four patients complained of visual toxicity characterized by a decrease in visual acuity, loss of color vision and night blindness. In these patients there was a decrease in visual acuity, and the Farnsworth's test revealed a tritanopy (yellow-blue axis impairment); 1 patient also showed retinal pigmentary changes. A fifth patient complained of bilateral and severe neurosensorial deafness. Patients improved clinically upon drug-withdrawal. We recommend careful monitoring of audiovisual toxicity in patients with end-stage renal disease receiving this drug.
Cases
A
A
Nephrology Service, Hospital Clínic i Provincial, Barcelona, Spain.
Kelly
J
J
Sabater
J
J
Campistol
J M
JM
Torras
A
A
Montoliu
J
J
López
I
I
Revert
L
L
D000208:Acute Disease; D000328:Adult; D000368:Aged; D003676:Deferoxamine / Q000009:adverse effects*; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced*; D006312:Hearing Loss, Bilateral / Q000139:chemically induced*; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008875:Middle Aged; D014786:Vision Disorders / Q000139:chemically induced*; D014792:Visual Acuity / Q000187:drug effects
D003676:Deferoxamine